• Je něco špatně v tomto záznamu ?

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

Zdenek Racil, Jana Winterova, Michal Kouba, Pavel Zak, Ludmila Malaskova, Lucie Buresova, Martina Toskova, Martina Lengerova, Iva Kocmanova, Barbora Weinbergerova, Shira Timilsina, Monika Rolencova, Petr Cetkovsky, Jiri Mayer

. 2012 ; 55 (6) : 483-492.

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13012732

Grantová podpora
NS10442 MZ0 CEP - Centrální evidence projektů
NS10441 MZ0 CEP - Centrální evidence projektů

The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematological patients (median 3 samples/patient; range 1-27) receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA) (46.3% of samples), empirical therapy (12.9%) or prophylaxis (40.8%). A high-pressure liquid chromatography assay was used to analyse voriconazole concentrations. Clinical and laboratory data were analysed retrospectively. The median of the detected voriconazole plasma concentration was 1.00 μg ml(-1) (range <0.20-13.47 μg ml(-1)). Significant inter- and intra-patients variability of measured concentrations (81.9% and 50.5%) were identified. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration, age, gender, CYP2C19*2 genotype, gastrointestinal tract abnormality, administration via nasogastric tube, serum creatinine, and liver enzymes. However, per patient analysis identified significant role of individual voriconazole dose and drug form change on measured plasma concentration. Measured voriconazole concentrations did not correlate with the treatment outcome of patients with IA. We only identified a limited number of adverse events related to voriconazole therapy; however, the median plasma concentration was not different from concentrations measured in samples without reported toxicity. Our retrospective study has suggested that routine monitoring of voriconazole plasma concentrations has probably only a limited role in daily haematological practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13012732
003      
CZ-PrNML
005      
20141013085412.0
007      
ta
008      
130404s2012 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1439-0507.2012.02186.x $2 doi
035    __
$a (PubMed)22429709
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Racil, Zdenek $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic; CEITEC – Central European Institute of Technology, Masaryk University, Brno, Czech Republic. zracil@fnbrno.cz
245    10
$a Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience / $c Zdenek Racil, Jana Winterova, Michal Kouba, Pavel Zak, Ludmila Malaskova, Lucie Buresova, Martina Toskova, Martina Lengerova, Iva Kocmanova, Barbora Weinbergerova, Shira Timilsina, Monika Rolencova, Petr Cetkovsky, Jiri Mayer
520    9_
$a The objective of this retrospective study was to evaluate results from voriconazole therapeutic drug monitoring (TDM) in haematological patients in routine clinical practice. Between 2005 and 2010, 1228 blood samples were obtained from 264 haematological patients (median 3 samples/patient; range 1-27) receiving voriconazole for targeted/preemptive treatment of invasive aspergillosis (IA) (46.3% of samples), empirical therapy (12.9%) or prophylaxis (40.8%). A high-pressure liquid chromatography assay was used to analyse voriconazole concentrations. Clinical and laboratory data were analysed retrospectively. The median of the detected voriconazole plasma concentration was 1.00 μg ml(-1) (range <0.20-13.47 μg ml(-1)). Significant inter- and intra-patients variability of measured concentrations (81.9% and 50.5%) were identified. With the exception of omeprazole administration, there was no relevant relationship between measured voriconazole concentrations and drug dose, route administration, age, gender, CYP2C19*2 genotype, gastrointestinal tract abnormality, administration via nasogastric tube, serum creatinine, and liver enzymes. However, per patient analysis identified significant role of individual voriconazole dose and drug form change on measured plasma concentration. Measured voriconazole concentrations did not correlate with the treatment outcome of patients with IA. We only identified a limited number of adverse events related to voriconazole therapy; however, the median plasma concentration was not different from concentrations measured in samples without reported toxicity. Our retrospective study has suggested that routine monitoring of voriconazole plasma concentrations has probably only a limited role in daily haematological practice.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antifungální látky $x aplikace a dávkování $x škodlivé účinky $x krev $7 D000935
650    _2
$a aromatické hydroxylasy $x genetika $7 D001189
650    _2
$a aspergilóza $x komplikace $x farmakoterapie $x genetika $7 D001228
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    12
$a monitorování léčiv $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krevní nemoci $x komplikace $x farmakoterapie $x genetika $7 D006402
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $x krev $7 D011743
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a triazoly $x aplikace a dávkování $x škodlivé účinky $x krev $7 D014230
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Winterova, Jana $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Kouba, Michal $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Zak, Pavel $u Department of Medicine 2 – Clinical Hematology, Faculty of Medicine, University Hospital and Charles University, Hradec Kralove, Czech Republic
700    1_
$a Malaskova, Ludmila $u Department of Clinical Biochemistry, University Hospital Brno, Brno, Czech Republic
700    1_
$a Buresova, Lucie $u Faculty of Medicine and Science, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Toskova, Martina $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Lengerova, Martina $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Kocmanova, Iva $u Department of Microbiology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Weinbergerova, Barbora $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Timilsina, Shira $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Rolencova, Monika $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Cetkovsky, Petr $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Mayer, Jiri $u Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic; CEITEC – Central European Institute of Technology, Masaryk University, Brno, Czech Republic
773    0_
$w MED00010272 $t Mycoses $x 1439-0507 $g Roč. 55, č. 6 (2012), s. 483-492
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22429709 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20141013085803 $b ABA008
999    __
$a ok $b bmc $g 975930 $s 811013
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 55 $c 6 $d 483-492 $i 1439-0507 $m Mycoses $n Mycoses $x MED00010272
GRA    __
$a NS10442 $p MZ0
GRA    __
$a NS10441 $p MZ0
LZP    __
$a Pubmed-20130404

Najít záznam

Citační ukazatele

Možnosti archivace